Fast Five Quiz: Menopause and Hormone Therapy

Richard Scott Lucidi, MD, FACOG


September 01, 2022

During the menopausal transition, most women experience vasomotor symptoms. The primary indication for systemic HT is for relief of vasomotor symptoms that are moderate to severe in severity and interfere with daily activities. According to the North American Menopause Society (NAMS), HT may be used in women without contraindications that are < 60 years and who are within 10 years of menopause onset. Studies have shown that HT reduces the severity and frequency of hot flashes. Other menopausal symptoms that respond to HT include urogenital symptoms, sleep disturbances, and depression. In women at high risk for fracture who are unable to tolerate other therapies, HT may be considered for the prevention of osteoporosis.

According to the American College of Cardiology, HT is not recommended for primary or secondary prevention of cardiovascular disease. This recommendation was made following the HERS study and the WHI study, which failed to demonstrate any cardiovascular benefits from HT and suggested potential harm. In addition, HT is not recommended for the prevention of diabetes.

Learn more about menopausal HT.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.